GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » DOD Biotech PCL (BKK:DOD-F) » Definitions » Change In Payables And Accrued Expense

DOD Biotech PCL (BKK:DOD-F) Change In Payables And Accrued Expense : ฿-55.5 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is DOD Biotech PCL Change In Payables And Accrued Expense?

DOD Biotech PCL's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was ฿-22.3 Mil. It means DOD Biotech PCL's Accounts Payable & Accrued Expense declined by ฿22.3 Mil from Dec. 2023 to Mar. 2024 .

DOD Biotech PCL's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was ฿-8.9 Mil. It means DOD Biotech PCL's Accounts Payable & Accrued Expense declined by ฿8.9 Mil from Dec. 2022 to Dec. 2023 .


DOD Biotech PCL Change In Payables And Accrued Expense Historical Data

The historical data trend for DOD Biotech PCL's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DOD Biotech PCL Change In Payables And Accrued Expense Chart

DOD Biotech PCL Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 77.01 121.73 -116.82 -7.65 -8.93

DOD Biotech PCL Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.35 -20.14 -0.45 -12.68 -22.26

DOD Biotech PCL Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿-55.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DOD Biotech PCL Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of DOD Biotech PCL's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


DOD Biotech PCL (BKK:DOD-F) Business Description

Traded in Other Exchanges
Address
No.111, Moo 2, Tumbol Taa jeen, Amphor Muengsamutsakhon, Samut Sakhon, THA, 74000
DOD Biotech PCL is engaged in the business of food supplements and health drinks of all kinds. The company offers Skincare products, Dietary supplements, Healthy supplements, and Own branded products. The majority of the company's revenue is derived from the supplementary business segment within Thailand. The segments of the group are Supplementary business, Manufacturing cosmetic and Network marketing, Manufacturing Extraction business, and others, of which a majority of revenue is derived from the Supplementary business segment.

DOD Biotech PCL (BKK:DOD-F) Headlines

No Headlines